Equity Profile

GILD

Gilead Sciences, Inc.

Health CareBiotechnology$160.4B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Gilead Sciences, Inc. is a biotechnology company that focuses on developing innovative medicines for serious diseases, particularly in the fields of HIV, liver diseases, and oncology....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors will closely monitor this quarter.

Expected to be around $2.03.

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and sales, which is crucial for sustaining long-term growth.

Not available.

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

GILD Q2-2026 Earnings Preview

Context

Company Snapshot

Gilead Sciences, Inc. is a biotechnology company that focuses on developing innovative medicines for serious diseases, particularly in the fields of HIV, liver diseases, and oncology. With a market cap of $162 billion, Gilead plays a significant role in the healthcare sector, addressing critical health challenges and contributing to advancements in treatment options.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+11.92%

Avg Stock Reaction

-0.05%

Last Quarter Recap

In the last quarter, Gilead reported an EPS of $2.03, exceeding expectations by 7.69%. However, the stock experienced a decline of 1.64% the following day, indicating mixed investor sentiment.

Management Promises & Guidance

Continued focus on expanding its product offerings.
Commitment to advancing clinical trials for new therapies.
Plans to enhance operational efficiency.

Expectations

Wall Street Expectations

Overall, expectations for Gilead's upcoming earnings are cautious, with investors looking for solid performance but wary of potential challenges in revenue growth.

Bull Case

If Gilead can demonstrate strong EPS growth and positive updates on its product pipeline, it could lead to increased investor confidence and a stock price rally.

Bear Case

On the other hand, if the company fails to meet EPS expectations or provides disappointing updates on its pipeline, it could result in a significant drop in stock price.

Key Metrics to Watch

Earnings Per Share (EPS)

Expected to be around $2.03.

EPS is a key indicator of the company's profitability and financial health, which investors will closely monitor this quarter.

Revenue Growth

Not available.

Revenue growth reflects the company's ability to expand its market presence and sales, which is crucial for sustaining long-term growth.

Product Pipeline Updates

Not available.

Updates on the product pipeline can indicate future revenue potential and the company's innovation capabilities.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected EPS for this quarter, and how does it compare to previous quarters?

EPS is a crucial measure of profitability, and any significant deviation from expectations could impact investor sentiment.

What updates can management provide on the product pipeline and upcoming clinical trials?

Insights into the product pipeline can indicate future growth potential and the company's ability to innovate.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Gilead's potential for higher-than-expected EPS due to strong sales in its HIV and oncology segments, which have shown resilience in recent quarters.

Supporting Evidence

The company has consistently beaten EPS estimates over the last several quarters, indicating strong operational performance.

Options pricing suggests a larger move than historical averages, hinting at potential surprises.

Insider selling could reflect personal financial decisions rather than a lack of confidence in the company's future.

Key Risk

If the product pipeline shows significant advancements or unexpected demand, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating Gilead's ability to sustain growth amid competitive pressures and evolving healthcare needs.

Bull Confirmed If

An EPS of $2.10 or higher would confirm strong performance and investor confidence.

Bear Confirmed If

An EPS below $1.90 would raise concerns about profitability and growth prospects.

Pre-Earnings Positioning

Options Market

Implied Move

±11.88%

Historical Avg

±1.2%

Pricing rich

The options market is pricing in a significant move, suggesting that investors anticipate volatility around the earnings report.

Options are pricing ±3.8% while GILD has averaged ±1.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

22.3%

Calls (429K)P/C Ratio: 0.42Puts (148K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 14 of 27 (52%)

This setup has occurred 30 times across Health Care in the last 2 years. 14 of 27 faded and 13 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.8%, with a raw directional average of +2.8% (modestly positive historical bias).

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$845,760.00

6,000 sh

2 insiders

Net

$845,760.00

Net selling

Most Active Insiders· 2 open-market trades

Chief Financial OfficerDickinson Andrew D
$422,880.00

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Gilead beats expectations, history suggests a potential average move of +1.16%, confirming a positive outlook.

In-Line / Cautious

If results are in line but management provides cautious commentary, the stock may experience muted movement.

Miss

A miss could lead to a decline, with historical data indicating a potential average drop of -0.05%.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

D-NJJosh GottheimerRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any commentary on sales growth in HIV and oncology products.
2Updates on clinical trial results for new therapies.
3Management's outlook on competitive pressures in the biotech space.
4Details on operational efficiencies and cost management strategies.
5Insights into future product launches and market expansion plans.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

Gilead Sciences, Inc. is a biotechnology company that focuses on developing innovative medicines for serious diseases, particularly in the fields of HIV, liver diseases, and oncology....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors will closely monitor this quarter.

Expected to be around $2.03.

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and sales, which is crucial for sustaining long-term growth.

Not available.

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

GILD Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+11.92%

Avg Stock Reaction

-0.05%

Last Quarter Recap

In the last quarter, Gilead reported an EPS of $2.03, exceeding expectations by 7.69%. However, the stock experienced a decline of 1.64% the following day, indicating mixed investor sentiment.

Management Promises & Guidance

Continued focus on expanding its product offerings.
Commitment to advancing clinical trials for new therapies.
Plans to enhance operational efficiency.

Expectations

Wall Street Expectations

Overall, expectations for Gilead's upcoming earnings are cautious, with investors looking for solid performance but wary of potential challenges in revenue growth.

Bull Case

If Gilead can demonstrate strong EPS growth and positive updates on its product pipeline, it could lead to increased investor confidence and a stock price rally.

Bear Case

On the other hand, if the company fails to meet EPS expectations or provides disappointing updates on its pipeline, it could result in a significant drop in stock price.

Key Metrics to Watch

Earnings Per Share (EPS)

Expected to be around $2.03.

EPS is a key indicator of the company's profitability and financial health, which investors will closely monitor this quarter.

Revenue Growth

Not available.

Revenue growth reflects the company's ability to expand its market presence and sales, which is crucial for sustaining long-term growth.

Product Pipeline Updates

Not available.

Updates on the product pipeline can indicate future revenue potential and the company's innovation capabilities.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected EPS for this quarter, and how does it compare to previous quarters?

EPS is a crucial measure of profitability, and any significant deviation from expectations could impact investor sentiment.

What updates can management provide on the product pipeline and upcoming clinical trials?

Insights into the product pipeline can indicate future growth potential and the company's ability to innovate.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Gilead's potential for higher-than-expected EPS due to strong sales in its HIV and oncology segments, which have shown resilience in recent quarters.

Supporting Evidence

The company has consistently beaten EPS estimates over the last several quarters, indicating strong operational performance.

Options pricing suggests a larger move than historical averages, hinting at potential surprises.

Insider selling could reflect personal financial decisions rather than a lack of confidence in the company's future.

Key Risk

If the product pipeline shows significant advancements or unexpected demand, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating Gilead's ability to sustain growth amid competitive pressures and evolving healthcare needs.

Bull Confirmed If

An EPS of $2.10 or higher would confirm strong performance and investor confidence.

Bear Confirmed If

An EPS below $1.90 would raise concerns about profitability and growth prospects.

Pre-Earnings Positioning

Options Market

Implied Move

±11.88%

Historical Avg

±1.2%

Pricing rich

The options market is pricing in a significant move, suggesting that investors anticipate volatility around the earnings report.

Options are pricing ±3.8% while GILD has averaged ±1.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

22.3%

Calls (429K)P/C Ratio: 0.42Puts (148K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 14 of 27 (52%)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$845,760.00

6,000 sh

2 insiders

Net

$845,760.00

Net selling

Most Active Insiders· 2 open-market trades

Chief Financial OfficerDickinson Andrew D
$422,880.00

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Gilead beats expectations, history suggests a potential average move of +1.16%, confirming a positive outlook.

In-Line / Cautious

If results are in line but management provides cautious commentary, the stock may experience muted movement.

Miss

A miss could lead to a decline, with historical data indicating a potential average drop of -0.05%.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

D-NJJosh GottheimerRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any commentary on sales growth in HIV and oncology products.
2Updates on clinical trial results for new therapies.
3Management's outlook on competitive pressures in the biotech space.
4Details on operational efficiencies and cost management strategies.
5Insights into future product launches and market expansion plans.